Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1887
Peer-review started: December 30, 2019
First decision: April 1, 2020
Revised: April 7, 2020
Accepted: April 22, 2020
Article in press: April 22, 2020
Published online: May 26, 2020
Processing time: 146 Days and 20.4 Hours
Leimyosarcoma of the pelvic cavity heavily affects the health and life of women, but clinical characteristics and relevant diagnosis of the disease are still unclear. It is necessary to carry out clinical research related to pelvic leiomyosarcoma.
Preoperative diagnosis of pelvic leiomyosarcoma is very difficult, and only the pathological examination after operation can provide an accurate diagnosis for this disease. We would like to study the causes affecting diagnosis and factors affecting outcomes of those patients.
This study aimed to identify the outcomes and relevant perioperative evaluation of patients with pelvic leiomyosarcoma.
We used Kaplan-Meier method to determine progression-free survival and overall survival rates. Univariate and multivariate Cox proportional hazards models were used to comprehensively analyse the prognostic factors
The results indicated that serum biomarkers had limited ability in leiomyosarcoma diagnosis and ultrasonography could not accurately differentiate leiomyosarcoma from uterine leiomyoma. However, most of the recurrent lesions could be detected using ultrasonography. FIGO stage was significantly associated with poor progression-free survival in the univariate and multivariate analyses.
Serum tumour markers and ultrasonography cannot accurately diagnose pelvic leiomyosarcoma. Ultrasonography remains valuable in monitoring recurrence. FIGO stage is significantly associated with patient outcomes.
Although accurate preoperative diagnosis of pelvic leiomyosarcoma was very difficult, our results showed that FIGO stage was significantly related to prognosis. Therefore, improving the early diagnosis rate is a promising field in the future.